Benzinga

Benzinga

Benzinga

viernes, septiembre 04

Protagonist Therapeutics Inc

PTGXNASDAQ
Trade with Public
Trade with Public
$148.80
2.721.86%
al cierre: Sep 2, 5:00 PM EST
$150.00
3.922.68%
Premercado: 4:09 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Protagonist Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Protagonist Therapeutics (PTGX).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

3S.Buy
14Buy
Consensus RatingBuy# Analysts17Avg. Consensus PT$129Upside to Avg. PT-14.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026BarclaysEtzer DaroutPT RaiseOverweight$153→$180
Sep 1, 2026BMO CapitalEtzer DaroutPT RaiseOutperform$178→$190
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.
Benzinga Newsdesk

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised
Avi Kapoor

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved